John Stanford
Psychiatric/Mental Health · Tulsa, OKNPI 1881286995
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Johnson & Johnson at 25.5% of the total.
Across 61 payments — averaging $82.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$728
- Teva Pharmaceuticals USA, Inc.$680
- Axsome Therapeutics, Inc.$531
- Otsuka America Pharmaceutical, Inc.$478
- Vanda Pharmaceuticals Inc.$345
- plus $973 from 7 others
What the payments were for
- Speaking & faculty fees$581%
- Food & beverage$4,95699%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 11 | $1,279 |
| AbbVie | 17 | $728 |
| Teva Pharmaceuticals USA, Inc. | 6 | $680 |
| Axsome Therapeutics, Inc. | 5 | $531 |
| Otsuka America Pharmaceutical, Inc. | 4 | $478 |
| Vanda Pharmaceuticals Inc. | 3 | $345 |
| Alkermes, Inc. | 2 | $231 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $199 |
| Supernus Pharmaceuticals, Inc. | 1 | $125 |
| Corium, LLC | 7 | $124 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Idorsia Pharmaceuticals US Inc | 1 | $115 |
| BD | 1 | $58 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,014 in reported general payments places this provider in the 80th percentile of 231 psychiatric/mental health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 17 | $517 |
| Hydroxyzine Hcl | 22 | $342 |
| Trazodone Hcl | 34 | $205 |
| Lamotrigine | 21 | $203 |
| Mirtazapine | 19 | $114 |
| Sertraline Hcl | 18 | $95 |
| Escitalopram Oxalate | 15 | $37 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $27 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Tulsa
- Fernanda CooleyTulsa$16K
- Pramila TraxlerTulsa$12K
- Sabrina ConleyTulsa$10K
- la Maria FolksTulsa$10K
- Emily MooreTulsa$9K
- Caroline LeithnerTulsa$7K
- Rebekah MackeyTulsa$5K
- Kari MurphyTulsa$5K
- Jordan GillinghamTulsa$5K
- Jennifer AycockTulsa$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.